Tag: lyme disease vaccine market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Lyme Disease Vaccine Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The lyme disease vaccine market has experienced substantial growth in recent years. Its value is projected to increase from $1.12 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be attributed to the rising occurrence of lyme disease in endemic areas, the limitations of past antibiotic-only treatment approaches, early-stage initiatives in vaccine research, a growing public awareness of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to reach $1.57 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth over the forecast period stems from the broader implementation of vaccination programs in endemic regions, increased investment in preventing infectious diseases, progress in next-generation vaccine platforms, a rise in the uptake of combination vaccines, and an intensified global concentration on controlling zoonotic diseases. Dominant trends during this period include advancements in recombinant vaccine technologies, a stronger emphasis on preventive immunization initiatives, an increase in clinical research for tick-borne diseases, a growing demand for long-lasting immunity solutions, and enhanced collaboration between public and private health organizations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=78493451&type=smp&name=Lyme%20Disease%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lyme Disease Vaccine Market Growth Backed By Core Demand Fundamentals

The rising incidence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market moving forward. Lyme disease, a tick-transmitted infection caused by Borrelia bacteria, can lead to symptoms such as fever, tiredness, skin rash, and potentially severe complications affecting joints, the heart, or the nervous system if not treated. The growth in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend tick living areas, leading to more human encounters with infected ticks. Lyme disease vaccines contribute to preventing the illness by preparing the immune system to identify and combat Borrelia bacteria, thereby lowering the chances of infection. These vaccines streamline disease management by offering enduring protection, which enhances overall public health outcomes. For example, in March 2025, the Centers for Disease Control and Prevention indicated that approximately 89,000 cases of Lyme disease were reported in the United States in 2023, while alternative estimations suggest that around 476,000 people might be diagnosed and treated for Lyme disease each year. Consequently, the increasing prevalence of Lyme disease is propelling the growth of the Lyme disease vaccine market.

Lyme Disease Vaccine Market Segment Landscape And Growth Outlook

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Lyme Disease Vaccine Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, such as booster vaccines, to address unmet medical needs, enhance immune protection, and simplify vaccination regimens. Booster vaccines are supplementary doses administered after the initial vaccination to restore or augment long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, confirmed the positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine designed to train the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies block the bacteria inside the tick, preventing infection in humans. The robust immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving prior annual booster doses, further demonstrating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is designed to provide continuous protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Lyme Disease Vaccine Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

View The Full Lyme Disease Vaccine Market Report:

https://thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lyme Disease Vaccine Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Lyme Disease Vaccine Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The lyme disease vaccine market has experienced substantial growth in recent years. Its value is projected to increase from $1.12 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be attributed to the rising occurrence of lyme disease in endemic areas, the limitations of past antibiotic-only treatment approaches, early-stage initiatives in vaccine research, a growing public awareness of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to reach $1.57 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth over the forecast period stems from the broader implementation of vaccination programs in endemic regions, increased investment in preventing infectious diseases, progress in next-generation vaccine platforms, a rise in the uptake of combination vaccines, and an intensified global concentration on controlling zoonotic diseases. Dominant trends during this period include advancements in recombinant vaccine technologies, a stronger emphasis on preventive immunization initiatives, an increase in clinical research for tick-borne diseases, a growing demand for long-lasting immunity solutions, and enhanced collaboration between public and private health organizations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=78493451&type=smp&name=Lyme%20Disease%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lyme Disease Vaccine Market Growth Backed By Core Demand Fundamentals

The rising incidence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market moving forward. Lyme disease, a tick-transmitted infection caused by Borrelia bacteria, can lead to symptoms such as fever, tiredness, skin rash, and potentially severe complications affecting joints, the heart, or the nervous system if not treated. The growth in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend tick living areas, leading to more human encounters with infected ticks. Lyme disease vaccines contribute to preventing the illness by preparing the immune system to identify and combat Borrelia bacteria, thereby lowering the chances of infection. These vaccines streamline disease management by offering enduring protection, which enhances overall public health outcomes. For example, in March 2025, the Centers for Disease Control and Prevention indicated that approximately 89,000 cases of Lyme disease were reported in the United States in 2023, while alternative estimations suggest that around 476,000 people might be diagnosed and treated for Lyme disease each year. Consequently, the increasing prevalence of Lyme disease is propelling the growth of the Lyme disease vaccine market.

Lyme Disease Vaccine Market Segment Landscape And Growth Outlook

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Lyme Disease Vaccine Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, such as booster vaccines, to address unmet medical needs, enhance immune protection, and simplify vaccination regimens. Booster vaccines are supplementary doses administered after the initial vaccination to restore or augment long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, confirmed the positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine designed to train the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies block the bacteria inside the tick, preventing infection in humans. The robust immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving prior annual booster doses, further demonstrating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is designed to provide continuous protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Lyme Disease Vaccine Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

View The Full Lyme Disease Vaccine Market Report:

https://thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lyme Disease Vaccine Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Lyme Disease Vaccine Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The lyme disease vaccine market has experienced substantial growth in recent years. Its value is projected to increase from $1.12 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be attributed to the rising occurrence of lyme disease in endemic areas, the limitations of past antibiotic-only treatment approaches, early-stage initiatives in vaccine research, a growing public awareness of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to reach $1.57 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth over the forecast period stems from the broader implementation of vaccination programs in endemic regions, increased investment in preventing infectious diseases, progress in next-generation vaccine platforms, a rise in the uptake of combination vaccines, and an intensified global concentration on controlling zoonotic diseases. Dominant trends during this period include advancements in recombinant vaccine technologies, a stronger emphasis on preventive immunization initiatives, an increase in clinical research for tick-borne diseases, a growing demand for long-lasting immunity solutions, and enhanced collaboration between public and private health organizations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=78493451&type=smp&name=Lyme%20Disease%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lyme Disease Vaccine Market Growth Backed By Core Demand Fundamentals

The rising incidence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market moving forward. Lyme disease, a tick-transmitted infection caused by Borrelia bacteria, can lead to symptoms such as fever, tiredness, skin rash, and potentially severe complications affecting joints, the heart, or the nervous system if not treated. The growth in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend tick living areas, leading to more human encounters with infected ticks. Lyme disease vaccines contribute to preventing the illness by preparing the immune system to identify and combat Borrelia bacteria, thereby lowering the chances of infection. These vaccines streamline disease management by offering enduring protection, which enhances overall public health outcomes. For example, in March 2025, the Centers for Disease Control and Prevention indicated that approximately 89,000 cases of Lyme disease were reported in the United States in 2023, while alternative estimations suggest that around 476,000 people might be diagnosed and treated for Lyme disease each year. Consequently, the increasing prevalence of Lyme disease is propelling the growth of the Lyme disease vaccine market.

Lyme Disease Vaccine Market Segment Landscape And Growth Outlook

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Lyme Disease Vaccine Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, such as booster vaccines, to address unmet medical needs, enhance immune protection, and simplify vaccination regimens. Booster vaccines are supplementary doses administered after the initial vaccination to restore or augment long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, confirmed the positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine designed to train the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies block the bacteria inside the tick, preventing infection in humans. The robust immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving prior annual booster doses, further demonstrating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is designed to provide continuous protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Lyme Disease Vaccine Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

View The Full Lyme Disease Vaccine Market Report:

https://thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Lyme Disease Vaccine Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lyme Disease Vaccine Market Expected To Reach $1.57 Billion By 2030 At 7% CAGR

The lyme disease vaccine market has experienced robust expansion in recent years, with projections indicating an increase from $1.12 billion in 2025 to $1.2 billion in 2026, representing a compound annual growth rate (CAGR) of 7.3%. This historic growth was driven by a rising number of lyme disease cases in endemic areas, the recognized shortcomings of relying solely on antibiotics for treatment, early-phase vaccine development efforts, heightened public understanding of tick-borne illnesses, and enhanced disease monitoring through public health systems.

The market for Lyme disease vaccines is projected to experience robust expansion over the coming years, reaching a valuation of $1.57 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. Several factors are fueling this anticipated growth during the forecast period, including the broadening of vaccination initiatives within high-risk regions, heightened funding allocated to combatting infectious diseases, the development of state-of-the-art vaccine technologies, a greater uptake of combination vaccines, and an intensified worldwide emphasis on the management of zoonotic diseases. Key developments shaping the industry during this timeframe encompass progress in recombinant vaccine platforms, a stronger push toward preventive immunization strategies, expanded clinical studies targeting tick-borne illnesses, a heightened focus on achieving durable immune responses, and enhanced partnerships between public health bodies and private sector organizations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Lyme Disease Vaccine Market Demand Drivers: What Is Fueling Industry Growth?

The growing number of Lyme disease cases is anticipated to drive forward the expansion of the Lyme disease vaccine market. This illness, transmitted by ticks and caused by Borrelia bacteria, manifests with symptoms such as fever, tiredness, and skin rashes, and can result in severe complications affecting the joints, heart, or nervous system if left untreated. The rise in incidence is linked to climate change, with warmer temperatures and milder winters extending tick habitats and boosting human contact with infected ticks. These vaccines protect against the disease by teaching the immune system to identify and combat Borrelia bacteria, thereby lowering the infection risk. They make disease management easier by offering lasting immunity and enhancing public health results. To illustrate, as per the Centers for Disease Control and Prevention, a US federal health agency, in March 2025, around 89,000 Lyme disease cases were documented in the United States in 2023, though other estimation methods suggest that close to 476,000 individuals may receive a diagnosis and treatment for the disease each year. Consequently, the rising prevalence of Lyme disease is fueling the growth of the market for its vaccines.

The upward trend in healthcare spending is set to boost the advancement of the Lyme disease vaccine market going forward. Healthcare expenditure encompasses all funds allocated to medical care, therapies, facilities, research, and public health programs aimed at sustaining or enhancing health. This spending increase is driven by the growing occurrence of chronic conditions that demand extended and expensive care. Higher healthcare costs benefit Lyme disease vaccine development by channeling more resources into research and clinical trials, which speeds up innovation and manufacturing. They also enable better vaccine technologies, improving availability and efficacy for groups at risk. For instance, the Office for National Statistics, a UK government agency, reported in May 2024 that total healthcare expenditure grew by 5.6% in nominal terms in 2023, marking a 0.9% increase compared to 2022. Thus, the rise in healthcare expenditure is propelling the growth of the Lyme disease vaccine market.

Lyme Disease Vaccine Market Segment Performance And Strategic Opportunities

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Lyme Disease Vaccine Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the Lyme disease vaccine sector are concentrating on advancing their late-stage pipeline products, including booster vaccines, with the goal of addressing unmet medical needs, improving immune responses, and streamlining immunization schedules. Booster vaccines refer to additional doses administered after the primary series to restore or boost long-term immunity. A case in point is Valneva SE, a biotechnology firm headquartered in France, which in September 2025 announced positive immunogenicity and safety findings from its ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This multivalent vaccine is designed to prime the immune system to generate antibodies targeting OspA proteins present on Borrelia bacteria. When an infected tick bites, these antibodies neutralize the bacteria within the tick, thus preventing transmission to humans. The robust immune reaction and favorable safety profile observed after a third booster dose were aligned with results from earlier annual boosters, reinforcing alignment with the expected advantages of a yearly vaccination regimen prior to each Lyme season. This booster approach is designed to ensure ongoing protection against Lyme disease, highlighting the possibility of an annual pre-season booster that simplifies prevention for individuals at risk.

Lyme Disease Vaccine Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Access The Complete Lyme Disease Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Lyme Disease Vaccine Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Lyme Disease Vaccine Market Compare Between 2026 And 2030?

The lyme disease vaccine market has shown robust expansion in recent years. Its size is projected to increase from $1.12 billion in 2025 to $1.2 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to several factors, including the increasing incidence of lyme disease in endemic regions, past limitations of antibiotic-only treatment approaches, early-stage vaccine research initiatives, growing awareness of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is projected for substantial expansion over the next few years. Its valuation is anticipated to reach $1.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected increase during the forecast period is driven by factors such as the broadening of vaccination programs in endemic regions, a rise in investment dedicated to infectious disease prevention, advancements in next-generation vaccine platforms, an increasing adoption of combination vaccines, and a growing global emphasis on controlling zoonotic diseases. Notable trends expected in this period include improvements in recombinant vaccine technologies, a greater focus on preventive immunization initiatives, an expansion of clinical research concerning tick-borne diseases, a stronger emphasis on solutions providing long-lasting immunity, and increased collaboration between public and private health organizations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

What Influential Factors Are Boosting The Lyme Disease Vaccine Market Demand?

The expanding occurrence of Lyme disease is anticipated to boost the Lyme disease vaccine market in the future. Lyme disease, an infection transmitted by ticks, is caused by Borrelia bacteria, manifesting as fever, fatigue, rashes, and potentially severe issues with joints, the heart, or nerves if not treated. The heightened incidence of Lyme disease stems from climate change, as warmer climates and less severe winters extend tick habitats, consequently increasing human contact with infected ticks. Lyme disease vaccines contribute to preventing the disease by preparing the immune system to identify and combat Borrelia bacteria, thereby lowering infection risks. They streamline disease management through sustained protection, which enhances overall public health. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal health agency, in 2023, around 89,000 cases of Lyme disease were reported in the United States, while estimates using other methods suggest that approximately 476,000 people may be diagnosed and treated for Lyme disease each year. Consequently, the rising prevalence of Lyme disease is propelling the expansion of the Lyme disease vaccine market.

How Is The Lyme Disease Vaccine Market Structured Across Different Market Segments?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

What Trends Are Affecting The Lyme Disease Vaccine Market Dynamics?

Companies operating in the Lyme disease vaccine market are focusing on advancing their late-stage product candidates, such as booster vaccines, to address unmet medical needs, enhance immune protection, and simplify vaccination regimens. Booster vaccines are additional doses administered after the initial vaccination to restore or augment long-term immunity. For instance, in September 2025, Valneva SE, a France-based biotechnology company, confirmed positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine that trains the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies block the bacteria inside the tick, preventing infection in humans. The strong immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving previous annual booster doses, further demonstrating compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. This booster strategy is intended to provide continued protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Who Are The Firms Contributing To The Lyme Disease Vaccine Market Ecosystem?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Access The Complete Lyme Disease Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Geographic Region Represents The Largest Lyme Disease Vaccine Market Share?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lyme Disease Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Lyme Disease Vaccine Market Expected To Scale Between 2026 And 2030?

The lyme disease vaccine market has shown robust expansion in recent years. It is anticipated to grow from $1.12 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical development of this market is attributable to a rising incidence of lyme disease in endemic areas, the past limitations of solely antibiotic-based treatment methods, initial vaccine research efforts, increased public understanding of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is anticipated to undergo significant expansion over the coming years. This market is projected to reach $1.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This predicted growth can be ascribed to several factors, including the spread of vaccination initiatives in regions where the disease is prevalent, greater financial commitment towards preventing infectious diseases, progress in developing advanced vaccine technologies, an uptick in the use of combination vaccines, and an intensified worldwide effort to manage zoonotic diseases. Key developments expected during this period involve improvements in recombinant vaccine technologies, a heightened emphasis on proactive immunization strategies, an increase in clinical studies for illnesses transmitted by ticks, a growing demand for enduring immunity options, and strengthening partnerships between public and private health entities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Major Drivers Are Influencing The Expansion Of The Lyme Disease Vaccine Market?

The rising incidence of Lyme disease is projected to fuel the expansion of the Lyme disease vaccine market moving forward. Lyme disease, a tick-borne ailment caused by Borrelia bacteria, manifests with fever, fatigue, and a rash, and can potentially lead to severe joint, heart, or neurological issues if left untreated. This increased prevalence of Lyme disease is attributed to climate change, where warmer temperatures and milder winters extend tick habitats, thereby heightening human exposure to infected ticks. Lyme disease vaccines contribute to prevention by educating the immune system to recognize and combat Borrelia bacteria, thereby lowering the chances of infection. They simplify the management of the disease by offering long-term protection, which enhances public health outcomes. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal health agency, approximately 89,000 cases of Lyme disease were reported in the United States in 2023, while alternative estimation methods suggest that around 476,000 individuals might be diagnosed and treated for Lyme disease annually. Therefore, the growing prevalence of Lyme disease is a primary driver for the Lyme disease vaccine market’s growth.

What Segment Categories Shape The Lyme Disease Vaccine Market Segment Landscape?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Which Trends Are Shaping The Lyme Disease Vaccine Market?

Leading companies within the Lyme disease vaccine market are concentrating on developing their advanced product candidates, particularly booster vaccines, with the aim of addressing medical gaps, bolstering immune defense, and streamlining vaccination schedules. Booster vaccines are supplemental doses administered following initial immunization to re-establish or strengthen sustained immunity. For example, in September 2025, Valneva SE, a France-based biotechnology firm, verified encouraging immunogenicity and safety results from its continuing Phase 2 study for the Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine designed to instruct the immune system to generate antibodies targeting OspA proteins found on Borrelia bacteria. When a tick bite occurs, these antibodies intercept the bacteria within the tick, thereby preventing human infection. The robust immune reaction and positive safety profile observed after a third booster dose mirrored findings from earlier annual booster doses, further confirming its alignment with the expected advantages of a yearly vaccination before each Lyme season. This booster approach seeks to offer ongoing protection against Lyme disease, highlighting the possibility of an annual pre-exposure season booster to simplify safeguarding for individuals at risk.

Who Are The Companies Operating Across The Lyme Disease Vaccine Market Value Chain?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Get The Full Lyme Disease Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Represents The Largest Share Of The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lyme Disease Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Lyme Disease Vaccine Market During The Forecast Period 2026–2030?

The lyme disease vaccine market has demonstrated strong growth in recent years. This market is projected to expand from $1.12 billion in 2025 to $1.2 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. The historical expansion can be attributed to factors such as the increasing occurrence of lyme disease in endemic regions, past limitations of antibiotic-only treatment methods, early initiatives in vaccine research, a growing understanding of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $1.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth during the forecast period is fueled by several factors, including the broadening of vaccination initiatives in regions where the disease is prevalent, a surge in funding for infectious disease prevention, the evolution of advanced vaccine platforms, the increasing use of combination vaccines, and an intensified worldwide emphasis on controlling zoonotic diseases. Key trends anticipated over this period encompass improvements in recombinant vaccine technologies, a heightened dedication to preventive immunization strategies, an expansion of clinical investigations into tick-borne illnesses, a greater focus on developing solutions for sustained immunity, and an increase in partnerships between public and private healthcare entities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Major Factors Are Driving The Expansion Of The Lyme Disease Vaccine Market?

The rising occurrence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market in the future. Lyme disease, an infection transmitted by ticks caused by Borrelia bacteria, manifests as fever, tiredness, skin rash, and potentially severe joint, cardiac, or neurological issues if left untreated. This rise in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend the areas where ticks can live, leading to more human contact with infected ticks. Lyme disease vaccines contribute to prevention by educating the immune system to identify and combat Borrelia bacteria, thereby lowering infection risks. They streamline disease management through sustained protection, which enhances overall public health. For example, in March 2025, the Centers for Disease Control and Prevention, a US-based federal health agency, reported about 89,000 cases of Lyme disease in the United States in 2023, while alternative estimation methods suggest that around 476,000 people might be diagnosed and treated for Lyme disease annually. Consequently, the growing prevalence of Lyme disease is a key factor propelling the growth of the Lyme disease vaccine market. The increasing outlay on healthcare is also projected to stimulate the expansion of the Lyme disease vaccine market. Healthcare expenditure encompasses the total financial investment in medical services, treatments, facilities, research endeavors, and public health programs aimed at maintaining or improving population health. The heightened need for healthcare spending stems from the growing incidence of chronic conditions that demand extended and expensive care. Elevated healthcare expenditure facilitates the progress of Lyme disease vaccine development by ensuring greater financial support for research and clinical trials, thus speeding up innovation and manufacturing. It also backs advanced vaccine technologies, thereby improving their availability and efficacy for populations at risk. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, representing a 0.9% growth compared to 2022. Consequently, the upward trend in healthcare spending is a significant factor propelling the growth of the Lyme disease vaccine market.

What Market Segments Are Evaluated Within The Lyme Disease Vaccine Market?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

What Industry Trends Are Redefining The Lyme Disease Vaccine Market?

Leading companies active in the Lyme disease vaccine market are concentrating on advancing their product candidates in late-age development, such as booster vaccines, to address unmet medical requirements, improve immune defense, and simplify vaccination protocols. Booster vaccines represent additional doses administered after the initial immunization to re-establish or enhance long-term immunity. For instance, in September 2025, Valneva SE, a France-based biotechnology company, affirmed positive immunogenicity and safety findings from the ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This vaccine is multivalent, designed to train the immune system to produce antibodies against OspA proteins located on Borrelia bacteria. When a tick bites, these antibodies impede the bacteria inside the tick, thereby preventing human infection. The strong immune response and favorable safety profile observed after a third booster dose were in line with those reported after receiving prior annual booster doses, further indicating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is intended to provide ongoing protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for individuals facing risk.

Who Are The Top Market Participants Influencing The Lyme Disease Vaccine Market?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Read the full lyme disease vaccine market report here:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Currently Holds The Largest Share Of The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lyme Disease Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Lyme Disease Vaccine Market During The Forecast Period 2026–2030?

The lyme disease vaccine market has demonstrated strong growth in recent years. This market is projected to expand from $1.12 billion in 2025 to $1.2 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. The historical expansion can be attributed to factors such as the increasing occurrence of lyme disease in endemic regions, past limitations of antibiotic-only treatment methods, early initiatives in vaccine research, a growing understanding of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $1.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth during the forecast period is fueled by several factors, including the broadening of vaccination initiatives in regions where the disease is prevalent, a surge in funding for infectious disease prevention, the evolution of advanced vaccine platforms, the increasing use of combination vaccines, and an intensified worldwide emphasis on controlling zoonotic diseases. Key trends anticipated over this period encompass improvements in recombinant vaccine technologies, a heightened dedication to preventive immunization strategies, an expansion of clinical investigations into tick-borne illnesses, a greater focus on developing solutions for sustained immunity, and an increase in partnerships between public and private healthcare entities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Major Factors Are Driving The Expansion Of The Lyme Disease Vaccine Market?

The rising occurrence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market in the future. Lyme disease, an infection transmitted by ticks caused by Borrelia bacteria, manifests as fever, tiredness, skin rash, and potentially severe joint, cardiac, or neurological issues if left untreated. This rise in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend the areas where ticks can live, leading to more human contact with infected ticks. Lyme disease vaccines contribute to prevention by educating the immune system to identify and combat Borrelia bacteria, thereby lowering infection risks. They streamline disease management through sustained protection, which enhances overall public health. For example, in March 2025, the Centers for Disease Control and Prevention, a US-based federal health agency, reported about 89,000 cases of Lyme disease in the United States in 2023, while alternative estimation methods suggest that around 476,000 people might be diagnosed and treated for Lyme disease annually. Consequently, the growing prevalence of Lyme disease is a key factor propelling the growth of the Lyme disease vaccine market. The increasing outlay on healthcare is also projected to stimulate the expansion of the Lyme disease vaccine market. Healthcare expenditure encompasses the total financial investment in medical services, treatments, facilities, research endeavors, and public health programs aimed at maintaining or improving population health. The heightened need for healthcare spending stems from the growing incidence of chronic conditions that demand extended and expensive care. Elevated healthcare expenditure facilitates the progress of Lyme disease vaccine development by ensuring greater financial support for research and clinical trials, thus speeding up innovation and manufacturing. It also backs advanced vaccine technologies, thereby improving their availability and efficacy for populations at risk. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, representing a 0.9% growth compared to 2022. Consequently, the upward trend in healthcare spending is a significant factor propelling the growth of the Lyme disease vaccine market.

What Market Segments Are Evaluated Within The Lyme Disease Vaccine Market?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

What Industry Trends Are Redefining The Lyme Disease Vaccine Market?

Leading companies active in the Lyme disease vaccine market are concentrating on advancing their product candidates in late-age development, such as booster vaccines, to address unmet medical requirements, improve immune defense, and simplify vaccination protocols. Booster vaccines represent additional doses administered after the initial immunization to re-establish or enhance long-term immunity. For instance, in September 2025, Valneva SE, a France-based biotechnology company, affirmed positive immunogenicity and safety findings from the ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This vaccine is multivalent, designed to train the immune system to produce antibodies against OspA proteins located on Borrelia bacteria. When a tick bites, these antibodies impede the bacteria inside the tick, thereby preventing human infection. The strong immune response and favorable safety profile observed after a third booster dose were in line with those reported after receiving prior annual booster doses, further indicating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is intended to provide ongoing protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for individuals facing risk.

Who Are The Top Market Participants Influencing The Lyme Disease Vaccine Market?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Read the full lyme disease vaccine market report here:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Currently Holds The Largest Share Of The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lyme Disease Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Lyme Disease Vaccine Market During The Forecast Period 2026–2030?

The lyme disease vaccine market has demonstrated strong growth in recent years. This market is projected to expand from $1.12 billion in 2025 to $1.2 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. The historical expansion can be attributed to factors such as the increasing occurrence of lyme disease in endemic regions, past limitations of antibiotic-only treatment methods, early initiatives in vaccine research, a growing understanding of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $1.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth during the forecast period is fueled by several factors, including the broadening of vaccination initiatives in regions where the disease is prevalent, a surge in funding for infectious disease prevention, the evolution of advanced vaccine platforms, the increasing use of combination vaccines, and an intensified worldwide emphasis on controlling zoonotic diseases. Key trends anticipated over this period encompass improvements in recombinant vaccine technologies, a heightened dedication to preventive immunization strategies, an expansion of clinical investigations into tick-borne illnesses, a greater focus on developing solutions for sustained immunity, and an increase in partnerships between public and private healthcare entities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Major Factors Are Driving The Expansion Of The Lyme Disease Vaccine Market?

The rising occurrence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market in the future. Lyme disease, an infection transmitted by ticks caused by Borrelia bacteria, manifests as fever, tiredness, skin rash, and potentially severe joint, cardiac, or neurological issues if left untreated. This rise in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend the areas where ticks can live, leading to more human contact with infected ticks. Lyme disease vaccines contribute to prevention by educating the immune system to identify and combat Borrelia bacteria, thereby lowering infection risks. They streamline disease management through sustained protection, which enhances overall public health. For example, in March 2025, the Centers for Disease Control and Prevention, a US-based federal health agency, reported about 89,000 cases of Lyme disease in the United States in 2023, while alternative estimation methods suggest that around 476,000 people might be diagnosed and treated for Lyme disease annually. Consequently, the growing prevalence of Lyme disease is a key factor propelling the growth of the Lyme disease vaccine market. The increasing outlay on healthcare is also projected to stimulate the expansion of the Lyme disease vaccine market. Healthcare expenditure encompasses the total financial investment in medical services, treatments, facilities, research endeavors, and public health programs aimed at maintaining or improving population health. The heightened need for healthcare spending stems from the growing incidence of chronic conditions that demand extended and expensive care. Elevated healthcare expenditure facilitates the progress of Lyme disease vaccine development by ensuring greater financial support for research and clinical trials, thus speeding up innovation and manufacturing. It also backs advanced vaccine technologies, thereby improving their availability and efficacy for populations at risk. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, representing a 0.9% growth compared to 2022. Consequently, the upward trend in healthcare spending is a significant factor propelling the growth of the Lyme disease vaccine market.

What Market Segments Are Evaluated Within The Lyme Disease Vaccine Market?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

What Industry Trends Are Redefining The Lyme Disease Vaccine Market?

Leading companies active in the Lyme disease vaccine market are concentrating on advancing their product candidates in late-age development, such as booster vaccines, to address unmet medical requirements, improve immune defense, and simplify vaccination protocols. Booster vaccines represent additional doses administered after the initial immunization to re-establish or enhance long-term immunity. For instance, in September 2025, Valneva SE, a France-based biotechnology company, affirmed positive immunogenicity and safety findings from the ongoing Phase 2 study of its Lyme disease vaccine candidate, VLA15. This vaccine is multivalent, designed to train the immune system to produce antibodies against OspA proteins located on Borrelia bacteria. When a tick bites, these antibodies impede the bacteria inside the tick, thereby preventing human infection. The strong immune response and favorable safety profile observed after a third booster dose were in line with those reported after receiving prior annual booster doses, further indicating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is intended to provide ongoing protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for individuals facing risk.

Who Are The Top Market Participants Influencing The Lyme Disease Vaccine Market?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Read the full lyme disease vaccine market report here:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Currently Holds The Largest Share Of The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lyme Disease Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the lyme disease vaccine market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Lyme Disease Vaccine Market’s size between 2026 and 2030?

The lyme disease vaccine market has demonstrated strong expansion in recent years. It is forecast to increase from $1.12 billion in 2025 to $1.2 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. The growth observed in previous periods stems from factors such as the increasing occurrence of lyme disease in endemic areas, the historical shortcomings of treatment approaches relying solely on antibiotics, initial vaccine research efforts, heightened awareness of tick-borne infections, and improvements in public health surveillance.

The Lyme disease vaccine market is anticipated to show significant expansion over the next few years, with projections indicating it will reach $1.57 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.0%. This forecasted growth can be linked to factors such as the broadening of vaccination initiatives in regions where the disease is prevalent, an uptick in funding for infectious disease prevention, advancements in next-generation vaccine platforms, the increasing acceptance of combination vaccines, and an elevated global focus on controlling zoonotic diseases. Dominant trends expected during this period include improvements in recombinant vaccine technologies, a stronger emphasis on preventive immunization campaigns, an expansion of clinical investigations into tick-borne diseases, a rising demand for solutions offering long-lasting immunity, and increased partnerships between public and private healthcare organizations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Drivers Are Shaping Strategic Decisions In The Lyme Disease Vaccine Market?

The rising incidence of Lyme disease is anticipated to drive the expansion of the Lyme disease vaccine market in the future. This tick-borne illness, stemming from Borrelia bacteria, can cause symptoms like fever, tiredness, rashes, and if not addressed, severe issues affecting joints, the heart, or nerves. The growing prevalence of Lyme disease is linked to climate change, where higher temperatures and less severe winters extend the areas ticks inhabit, thereby increasing human contact with infected ticks. Lyme disease vaccines assist in preventing the condition by preparing the immune system to identify and combat Borrelia bacteria, thus lowering infection risks. These vaccines streamline disease control by offering enduring protection and enhancing public health results. For example, in March 2025, data from the Centers for Disease Control and Prevention, a US-based federal health agency, indicated that about 89,000 cases of Lyme disease were reported in the United States in 2023. Additionally, alternative estimation methods suggest that approximately 476,000 people might be diagnosed and treated for Lyme disease annually. Consequently, the increasing prevalence of Lyme disease is a key factor boosting the Lyme disease vaccine market’s growth. The growing financial outlay on healthcare is predicted to boost the expansion of the Lyme disease vaccine market moving ahead. Healthcare expenditure encompasses the overall sum allocated to medical services, treatments, facilities, research, and public health campaigns aimed at maintaining or improving health results. The heightened need for healthcare spending stems from the increasing occurrence of chronic illnesses, which demand prolonged and expensive care. Enhanced healthcare spending facilitates the advancement of Lyme disease vaccines by channeling more funds into research and clinical trials, thereby accelerating innovation and manufacturing. It also backs sophisticated vaccine technologies, making them more accessible and effective for vulnerable groups. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that overall healthcare expenditure saw a 5.6% rise in nominal terms in 2023, representing a 0.9% increase compared to 2022. Consequently, the increasing healthcare expenditure is fueling the growth of the Lyme disease vaccine market.

What Segment Categories Are Covered In The Lyme Disease Vaccine Market?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Which Market Trends Are Opening Growth Opportunities In The Lyme Disease Vaccine Market?

Leading companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, such as booster vaccines, to meet existing medical needs, enhance immune defense, and simplify vaccination protocols. Booster vaccines are additional doses administered following initial immunization to restore or improve long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, confirmed encouraging immunogenicity and safety data from its ongoing Phase 2 study of the Lyme disease vaccine candidate, VLA15. This multivalent vaccine trains the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies effectively block the bacteria within the tick, preventing human infection. The strong immune response and favorable safety profile observed after a third booster dose were consistent with those reported after previous annual booster doses, further indicating its compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. This booster strategy is designed to provide continuous protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Which Major Industry Participants Are Leading The Lyme Disease Vaccine Market Growth?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Is Expected To Experience The Fastest Growth In The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lyme Disease Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model